Department of Orthopaedic Surgery, Atrium Health Musculoskeletal Institute, Charlotte, North Carolina.
Department of Orthopaedic Surgery, Atrium Health Musculoskeletal Institute; OrthoCarolina Research Institute, Charlotte, North Carolina.
J Opioid Manag. 2023 Nov-Dec;19(6):495-505. doi: 10.5055/jom.0834.
The objective is to quantify the rate of opioid and benzodiazepine prescribing for the diagnosis of shoulder osteoarthritis across a large healthcare system and to describe the impact of a clinical decision support intervention on prescribing patterns.
A prospective observational study.
One large healthcare system.
Adult patients presenting with shoulder osteoarthritis.
A clinical decision support intervention that presents an alert to prescribers when patients meet criteria for increased risk of opioid use disorder.
The percentage of patients receiving an opioid or benzodiazepine, the percentage who had at least one risk factor for misuse, and the percent of encounters in which the prescribing decision was influenced by the alert were the main outcome measures.
A total of 5,380 outpatient encounters with a diagnosis of shoulder osteoarthritis were included. Twenty-nine percent (n = 1,548) of these encounters resulted in an opioid or benzodiazepine prescription. One-third of those who received a prescription had at least one risk factor for prescription misuse. Patients were more likely to receive opioids from the emergency department or urgent care facilities (40 percent of encounters) compared to outpatient facilities (28 percent) (p < .0001). Forty-four percent of the opioid prescriptions were for "potent opioids" (morphine milliequivalent conversion factor > 1). Of the 612 encounters triggering an alert, the prescribing decision was influenced (modified or not prescribed) in 53 encounters (8.7 percent). All but four (0.65 percent) of these encounters resulted in an opioid prescription.
Despite evidence against routine opioid use for osteoarthritis, one-third of patients with a primary diagnosis of glenohumeral osteoarthritis received an opioid prescription. Of those who received a prescription, over one-third had a risk factor for opioid misuse. An electronic clinic decision support tool influenced the prescription in less than 10 percent of encounters.
在大型医疗保健系统中,定量评估用于诊断肩关节炎的阿片类药物和苯二氮䓬类药物的开具率,并描述临床决策支持干预对开具模式的影响。
前瞻性观察性研究。
一个大型医疗保健系统。
患有肩关节炎的成年患者。
当患者符合阿片类药物使用障碍风险增加的标准时,向开具者提供临床决策支持干预措施以发出警报。
接受阿片类药物或苯二氮䓬类药物的患者百分比、至少存在一种药物滥用风险因素的患者百分比,以及处方决策受警报影响的就诊百分比是主要观察指标。
共纳入 5380 例门诊就诊的肩关节炎患者。其中 29%(n=1548)的就诊开出了阿片类药物或苯二氮䓬类药物处方。接受处方的患者中有三分之一至少存在一种处方滥用风险因素。与门诊就诊相比,患者更有可能从急诊或紧急护理机构获得阿片类药物(40%的就诊)(p<0.0001)。44%的阿片类药物处方为“强效阿片类药物”(吗啡毫当量转换系数>1)。在触发警报的 612 次就诊中,有 53 次(8.7%)的处方决策受到影响(修改或未开具)。这些就诊中除 4 次(0.65%)外,均开出了阿片类药物处方。
尽管有证据表明常规使用阿片类药物治疗骨关节炎并不合适,但三分之一的原发性肩关节炎患者开具了阿片类药物处方。在接受处方的患者中,超过三分之一存在阿片类药物滥用风险因素。电子临床决策支持工具对不到 10%的就诊处方产生影响。